22 related articles for article (PubMed ID: 16458935)
1. Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.
Lehnhardt M; Klein-Hitpass L; Kuhnen C; Homann HH; Daigeler A; Steinau HU; Roehrs S; Schnoor L; Steinstraesser L; Mueller O
BMC Cancer; 2005 Jul; 5():74. PubMed ID: 16001973
[TBL] [Abstract][Full Text] [Related]
2. DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells.
Song S; Wang Y; Liu P
Int J Biol Sci; 2022; 18(3):1211-1219. PubMed ID: 35173548
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.
Kanno S; Maeda N; Tomizawa A; Yomogida S; Katoh T; Ishikawa M
Int J Oncol; 2012 Sep; 41(3):862-8. PubMed ID: 22684370
[TBL] [Abstract][Full Text] [Related]
4. Applications of microarray technology to Acute Myelogenous Leukemia.
Goswami RS; Sukhai MA; Thomas M; Reis PP; Kamel-Reid S
Cancer Inform; 2009; 7():13-28. PubMed ID: 19352456
[TBL] [Abstract][Full Text] [Related]
5. Balance of NF-kappaB and p38 MAPK is a determinant of radiosensitivity of the AML-2 and its doxorubicin-resistant cell lines.
Choi CH; Xu H; Bark H; Lee TB; Yun J; Kang SI; Oh YK
Leuk Res; 2007 Sep; 31(9):1267-76. PubMed ID: 17218010
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
7. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
8. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
9. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
10. Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis.
Song JH; Choi CH; Yeom HJ; Hwang SY; Kim TS
Life Sci; 2006 Jun; 79(2):193-202. PubMed ID: 16458935
[TBL] [Abstract][Full Text] [Related]
11. [Molecular targeting therapy by anti-VLA-4 monoclonal antibodies for AML].
Niitsu Y; Matsunaga T
Rinsho Ketsueki; 2005 Mar; 46(3):198-201. PubMed ID: 16447714
[No Abstract] [Full Text] [Related]
12. Endogenous tumor necrosis factor and doxorubicin sensitivity in leukemic patients.
Watanabe N
Leuk Lymphoma; 1998 Aug; 30(5-6):477-82. PubMed ID: 9711910
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
